MiMedx Group Inc (MDXG)

14.35
0.30 2.05
NASDAQ : Health Care
Prev Close 14.65
Open 15.24
Day Low/High 14.28 / 15.50
52 Wk Low/High 6.64 / 12.83
Volume 1.82M
Avg Volume 1.36M
Exchange NASDAQ
Shares Outstanding 110.87M
Market Cap 1.65B
EPS 0.10
P/E Ratio 106.21
Div & Yield N.A. (N.A)

Latest News

MiMedx Announces That Its Second Quarter Revenue Exceeds The Guidance Range

MiMedx Announces That Its Second Quarter Revenue Exceeds The Guidance Range

Q2 2017 REVENUE OF $76.4 MILLION IS 33% INCREASE OVER Q2 2016

MiMedx Group Stock Sees Short Interest Decline 11%

MiMedx Group Stock Sees Short Interest Decline 11%

The most recent short interest data has been released for the 06/30/2017 settlement date, which shows a 2,488,401 share decrease in total short interest for MiMedx Group Inc , to 20,263,818, a decrease of 10.94% since 06/15/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

First Week of August 18th Options Trading For MiMedx Group (MDXG)

Investors in MiMedx Group Inc saw new options become available this week, for the August 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDXG options chain for the new August 18th contracts and identified one put and one call contract of particular interest.

Scientific And Clinical Review Confirms Potential Of MiMedx DHACM Allografts For Regenerative Applications In Orthopedics

dHACM Allografts Retain Growth Factors And Bioactive Proteins Shown To Regulate Activity Of Cell Types, Including Stem Cells, That Are Critical To Orthopedic Repair Of Injured And Diseased Tissue

Integra's Massive Run-Up Expected to Continue as J&J's Surgical Business Joins the Fold

Integra's Massive Run-Up Expected to Continue as J&J's Surgical Business Joins the Fold

Integra announced in February its intent to acquire Codman Neurosurgery from Johnson & Johnson.

MiMedx Group Stock Sees Short Interest Fall 10.7%

The most recent short interest data has been released for the 04/28/2017 settlement date, which shows a 3,047,444 share decrease in total short interest for MiMedx Group Inc , to 25,316,460, a decrease of 10.74% since 04/13/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

MiMedx EpiFix® Receives Coverage From Kaiser Permanente

MORE THAN 317 MILLION COMMERCIAL LIVES AND MEDICARE/MEDICAID BENEFICIARIES NOW HAVE COVERAGE FOR MIMEDX EPIFIX

MiMedx Receives Innovative Technology Supplier Of The Year Award From Vizient, Inc.

The largest member-Driven Health Care Performance Improvement Company recognizes MiMedx for its positive impact on patient care

Merger Buzz Drives Akorn to Top of Health Chart in April

Merger Buzz Drives Akorn to Top of Health Chart in April

Other industry list-toppers included MiMedx, Cytokinetics, C.R. Bard, and Spectrum.

First Week of December 15th Options Trading For MiMedx Group (MDXG)

Investors in MiMedx Group Inc saw new options become available this week, for the December 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

MiMedx To Present At The European Wound Management Association Annual Conference

The Dynamic Impact of Epifix® Dehydrated Human Amnion/Chorion Membrane Allografts to be Presented at the Symposium

MiMedx Announces First Quarter 2017 Revenue To Exceed High End Of Guidance

Q1 2017 Revenue of $72.6 Million is 36% Increase Over Q1 2016

The Use Of MiMedx Allografts From The Company's Multiple Product Families To Be Presented At SAWC Conference

Poster Abstracts, Booth Education and Symposia Demonstrate Clinical and Cost Effective Results of MiMedx EpiFix®, AmnioFix®, EpiCord®, AmnioCord® and AmnioFill® Allografts in Healing Chronic and Acute Wounds

MiMedx Announces The Addition Of Luis A. Aguilar To Its Board Of Directors

NEWEST MIMEDX BOARD MEMBER IS FORMER COMMISSIONER OF THE U.S. SECURITIES & EXCHANGE COMMISSION

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACIW, ACM, BID, CAJ, CHT, GLRE, MBLY, MDXG, UEIC Downgrades: BSX, IAC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

MiMedx To Present At Canaccord's 12th Annual Musculoskeletal Conference

COMPANY ALSO TO EXHIBIT AT AMERICAN ASSOCIATION OF ORTHOPAEDIC SURGEONS (AAOS) MEETING

MiMedx Audit Committee Announces Completion Of Its Investigation

AUDIT COMMITTEE FINDS NO WRONGDOING BY MIMEDX MANAGEMENT

First Week of April 21st Options Trading For MiMedx Group

Investors in MiMedx Group Inc saw new options begin trading this week, for the April 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDXG options chain for the new April 21st contracts and identified the following put contract of particular interest.

MiMedx Group (MDXG) Shares Cross Above 200 DMA

In trading on Friday, shares of MiMedx Group Inc crossed above their 200 day moving average of $8.20, changing hands as high as $8.26 per share. MiMedx Group Inc shares are currently trading up about 0.9% on the day.

Benefits Of MiMedx DHACM Allograft Chronicled In Multiple Articles In February 2017 Supplement Edition Of Annals Of Plastic Surgery

ARTICLES BY RENOWNED PHYSICIANS DEMONSTRATE THE CLINICAL BENEFITS OF dHACM ALLOGRAFTS IN BURN MANAGEMENT AND THE TREATMENT OF DIFFICULT TO HEAL WOUNDS